Expression of RECK and matrix metalloproteinase-2 in ameloblastoma
Open Access
- 8 December 2009
- journal article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 9 (1), 427
- https://doi.org/10.1186/1471-2407-9-427
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Inhibition of ameloblastoma invasionin vitroandin vivoby inhibitor of metalloproteinase-2 activityJournal of Oral Pathology & Medicine, 2009
- Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancerEuropean Journal of Cancer, 2007
- Increased invasive potential and up-regulation of MMP-2 in MDA-MB-231 breast cancer cells expressing the beta3 integrin subunit.2007
- Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase AEndocrine-Related Cancer, 2006
- Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancerInternational Journal of Colorectal Disease, 2006
- Immunohistochemical detection of MT1-MMP, RECK, and EMMPRIN in ameloblastic tumorsJournal of Oral Pathology & Medicine, 2006
- The Membrane-Anchored Matrix Metalloproteinase (MMP) Regulator RECK in Combination with MMP-9 Serves as an Informative Prognostic Indicator for Colorectal CancerClinical Cancer Research, 2004
- Local invasiveness of ameloblastoma. Role played by matrix metalloproteinases and proliferative activityHistopathology, 2004
- RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis.2003
- The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and AngiogenesisCell, 2001